AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03928886 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral two-view (CC and MLO) FFDM (full field digital mammography) using standard compression mode
Description: Standard compression mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure.~Study-related compressions will consist of the first and second CC and MLO compressions performed on each breast during each subject's exam.
Study NCT00259012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole sodium enteric-coated spheroid suspension
Description: pediatric suspension taken daily x 7 days
Study NCT00490542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
Study NCT03488667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab
Description: Pembrolizumab, mFOLFOX Chemotherapy
Study NCT03488667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Treatment - mFOLFOX & Pembrolizumab
Description: Pembrolizumab, mFOLFOX Chemotherapy
Study NCT01868529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
Study NCT00033865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga, Relaxation Exercises, Sleep Hygiene
Description: Sleep hygiene and relaxation exercises, with additional yoga
Study NCT02293122 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Intervention is observational to two different diagnostic devices for which comparative readings of the corneal endothelium are being measured; the test device- the EM-3000 Specular Microscope against the Konan Robo-pachy F\&A Specular Microscope.
Study NCT01868529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
Study NCT01185548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Administered orally
Study NCT01185548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasisulam
Description: Administered intravenously
Study NCT02600286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EllaOne
Description: * 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months.
Study NCT04311658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate 40 MG
Description: one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG- IUD insertion
Study NCT02600286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EllaOne placebo
Description: * 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months.
Study NCT04389320 — intervention group
Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: assess its role in the coarse of covid 19 virus infection
Study NCT02476799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectus sheath block
Description: Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
Study NCT02476799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
Study NCT02476799 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bandage
Description: After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
Study NCT02476799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bandage
Description: After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
Study NCT02476799 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: IV-PCA containing Fentanyl and Ketorolac
Description: All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
Study NCT03219658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting education sessions
Description: If assigned to the parenting education session group, families will start with the 10-week group parenting education sessions and 2-4 home visits immediately after being enrolled. During this time, they will also come in for four one-on-one check-ins with the STOMP team. Each check-in will be approximately 1 hour. At least one parent/caregiver will attend weekly parenting sessions which will take place at SickKids. The Toronto Public Health Nurse will arrange 2-4 home visits with the family during the 6 month period of the study. The home visits will focus on helping to apply the messages and skills from the group sessions in their homes, and making connections in the neighbourhood to recreational or nutrition programs or other supports for the family.
Study NCT03708887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose omega-3 fatty acid supplementation
Description: Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year
Study NCT03708887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose omega-3 fatty acid supplementation
Description: Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
Study NCT03708887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control drug
Description: Matching placebo capsules,3 g/d by mouth for 1 year
Study NCT00924040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL22 (CAT-3888)
Description: 30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
Study NCT01062178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
Study NCT05986201 — intervention group
Intervention type: DEVICE
Intervention: TachoSil®
Description: TachoSil®, a carrier-bound fibrin sealant (CBFS), is a haemostatic tissue sealant composed of a collagen sponge, made from horse tendons, coated on one side with dried human fibrinogen and human thrombin.
Study NCT04311658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet of placebo vaginally 3 hours prior to LNG-IUD insertion
Study NCT01289496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon alpha-2a, Ribavirin
Description: * 4 weeks RBV priming;~* 24 or 48 weeks of Pegasys+Ribavirin (RBV) Treatment (depending on genotype);~* 24 weeks Follow-Up~Patients will receive PEGASYS® 180 µg in 0.5 mL (prefilled syringes) administered sc once weekly. Specific guidelines for adjusting the dose of PEGASYS® are provided in the product monograph.All PEGASYS® administrations will be via the sc route using sterile technique.~Ribavirin 200 mg tablets
Study NCT04343651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04343651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leronlimab (700mg)
Description: Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Study NCT00818259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: aprepitant
Description: aprepitant powder for suspension, 125 mg/sachet, PO
Study NCT00818259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: fosaprepitant
Description: fosaprepitant lyophilized powder for suspension, 115 mg/vial or 150 mg/vial, IV
Study NCT00818259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ondansetron
Description: ondansetron solution for infusion, IV, administered per local standard of care
Study NCT00818259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: ondansetron solution for infusion, IV, administered per local standard of care
Study NCT00818259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone solution for infusion, IV, administered per local standard of care
Study NCT00818259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone solution for infusion, IV, administered per local standard of care
Study NCT01506882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: LEV 250 mg, LEV 500 mg~* Frequency: Twice daily~* Route of Administration: Oral use
Study NCT02129673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS101 Insert Dose A
Description: Sustained release of latanoprost into the eye
Study NCT02129673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS101 Insert Dose B
Description: Sustained release of latanoprost into the eye
Study NCT02129673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS101 Insert Dose C
Description: Sustained release of latanoprost into the eye
Study NCT02129673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% eye drops
Description: Latanoprost 0.005% eye drops administered once daily on the eye
Study NCT01468311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auto stem cell transplant
Description: Auto stem cell transplant (ASCT) is given after 90Y-daclizumab
Study NCT02476799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV-PCA containing Fentanyl and Ketorolac
Description: All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
Study NCT02646397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosinopril
Description: Fosinopril is an angiotensin-converting enzyme inhibitor.
Study NCT02646397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benidipine
Description: Benidipine is a dihydropyridine-derived calcium channel blocker.
Study NCT02646397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide is a diuretic medication.
Study NCT04048369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rapid diagnosis of influenza in the emergency medical service
Description: Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).
Study NCT04048369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid diagnosis of influenza in the emergency medical service
Description: Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).
Study NCT02886208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measurement
Description: The intervention consists of diabetes prevention education sessions focusing on increasing physical activity and decreasing the intake of sugared drinks while increasing intake of fruits and vegetables. The 2-hr sessions occur weekly for 6 weeks. Height and weight is measured for each consenting participant at baseline and after 6 weeks. Participants are also asked to complete a short questionnaire to collect demographic and knowledge data. Outcome measures include: BMI, knowledge of physical activity and dietary habits conducive to diabetes prevention, and feelings of food insecurity.
Study NCT00477516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exposure to a high-calcium dialysate bath
Description: Subjects are exposed to a high calcium (3.5 mEq/L) dialysate bath for 150 minutes (part 1). At defined timepoints (0, 45, 90, and 150 min) blood is sampled for calcium, PTH, phosphorous, and FGF-23. At another (later) dialysis session (part 2), the process is repeated except that the subjects are exposed to a normal calcium bath (2.5 mEq/L). For each subject, results from part 1 are compared to the results from part 2.
Study NCT03044171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Laser therapy: it was used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and central-medial region of the incisors, canines and premolars.
Study NCT03044171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.1% Sodium Fluoride
Description: Fluoride therapy: 1.1% sodium fluoride 5000 ppm was applied for 5 minutes on the vestibular surface of all pre-bleached dental elements.
Study NCT01468311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM
Description: BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab
Study NCT01468311 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 111In-daclizumab
Description: 111In-daclizumab will be administered to patients with each therapeutic infusion of 90Y-daclizumab in order to define the distribution of radiolabeled daclizumab, and to allow visualization by scans.
Study NCT01468311 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 90Y-daclizumab
Description: 90Y-daclizumab administered with a fixed dose of pentetate calcium trisodium (Ca-DTPA) followed by BEAM Chemo and Auto stem cell transplant
Study NCT03044171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In-office dental bleaching
Description: Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
Study NCT03629548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early amniotomy
Description: 10 mg PGE2 vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
Study NCT03629548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: foley catheter balloon placement
Description: an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix and after placement of balloon catheter 10 mg PGE2 vaginal ovul will be inserted to the posterior fornix
Study NCT02865746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bethametasone
Description: The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
Study NCT02865746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
Study NCT00864097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 10 mg every 8 weeks (through Week 16)
Study NCT00864097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac
Description: Oral diclofenac SR 75 mg BID for 32 weeks
Study NCT00864097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 5 mg every 8 weeks (through Week 16)
Study NCT00864097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 2.5 mg every 8 weeks (through Week 16)
Study NCT00864097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: diclofenac
Description: Oral diclofenac SR 75 mg BID for 32 weeks
Study NCT01849744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-4718
Study NCT04134546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBD exoloration
Description: Early versus late intervention after biliary tract injury post cholecystectomy
Study NCT00864097 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo
Description: IV placebo to match tanezumab every 8 weeks (through Week 16)
Study NCT04206410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Multispecies probiotic mixture administered to patients according to the randomization list
Study NCT04206410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin as placebo
Study NCT00545545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Safety and efficacy of escalating doses
Description: Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle) and irinotecan on Day 1 of each week for 4 weeks with a 2-week rest. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT04150367 — intervention group
Intervention type: DRUG
Intervention: Isoniazid
Description: Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.
Study NCT04150367 — intervention group
Intervention type: DRUG
Intervention: Rifampicin
Description: Participants will get the dosage according to the instruction for use.
Study NCT04150367 — intervention group
Intervention type: DRUG
Intervention: Ethambutol
Description: Participants will get the dosage according to the instruction for use.
Study NCT00545545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Safety and efficacy of escalating doses.
Description: Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle). Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT04201080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: TRV250-20mg/ml
Description: TRV250 SC Injections
Study NCT04201080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC injections
Study NCT04201080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: TRV250 Dose 1
Description: Dose 1of3 TRV250
Study NCT01558141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration without flushing follicles with culture media
Description: Aspiration without flushing follicles with culture media.
Study NCT01558141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follicular Flushing
Description: Flushing follicles with embryo culture media prior to aspiration.
Study NCT02609139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Up to 400mg modified release tablets administered under fasted conditions
Study NCT02609139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 100mg modified release tablet administered under fasted conditions
Study NCT04201080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: TRV250 Dose 2
Description: Dose 2of3 TRV250 SC injections
Study NCT04201080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: TRV250 Dose 3
Description: Dose 3of3 TRV250 SC injections
Study NCT02676830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-312 100 mg
Description: Single oral dose
Study NCT02676830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-312 100 ug C14 IV
Description: microtracer dose containing ≤37 kBq (1000 nCi) \[14C\] given as a 5-ml IV push over 2 minutes
Study NCT03551587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibringe
Description: The Vibringe is the first endodontic sonic irrigation system that enables delivery and activation of the irrigation solution in the root canal, in only one step.
Study NCT04150367 — intervention group
Intervention type: DRUG
Intervention: Isoniazid
Description: . Participants will get the dosage according to the instruction for use.
Study NCT02609139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 20mg modified release tablet administered under fasted conditions
Study NCT02609139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Up to 400mg modified release tablets administered with high fat meal food intake
Study NCT02609139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 100mg modified released tablet administered with high fat meal food intake
Study NCT02609139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 20 mg modified release tablet administered with high fat meal food intake
Study NCT03705065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl
Description: Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)
Study NCT03192930 — intervention group
Intervention type: OTHER
Intervention: Hyperbaric exposure
Description: Hyperbaric exposure 4 ATA for 36 hours followed by 70 hours decompression